Healthcare Spending & Affordability
Expert articles and analysis related to healthcare spending & affordability.
AI Summary — Last 7 Days
Over the last week, scrutiny intensified around the financial sustainability of key value-based care (VBC) models, as new analyses revealed that the Oncology Care Model incurred net losses that surpassed any spending reductions achieved, raising questions about the cost-effectiveness of current VBC approaches. These developments come as CMS, under the leadership of Administrator Dr. Mehmet Oz in the Trump administration, continues to review and evaluate VBC programs following the transition of executive power in January 2025. The ongoing assessment by current CMS leadership reflects the administration’s focus on improving healthcare efficiency and cost-effectiveness.
Related Articles
Public Opinion on Prescription Drugs and Their Prices
This chart collection draws on recent KFF poll findings to provide an in-depth look at the public's attitudes toward prescription drugs and their prices. Results include the U.S. public’s experiences ...
What has been the main impact of MFN?
It is not bringing down US prices, but delaying launches in Europe. Reuters reports: Drug launches in EU markets fell by some 35% in the 10 months since Trump’s executive order, compared with the prev...
The Macroeconomic Budget and Health Care Projection Dashboard, Revisited: Can You Put the US Back on a Sustainable Path?
The Macroeconomic Budget and Health Care Projection Dashboard, Revisited: Can You Put the US Back on a Sustainable Path? American Enterprise Institute - AEI
Uninsured patients drive nearly 40% of healthcare collections: Cedar survey
Uninsured patients drive nearly 40% of healthcare collections: Cedar survey Fierce Healthcare
San Francisco Bay Area — Regional Market Report 2025
What comes next for price transparency rules?
In December 2025, HHS, alongside the Labor and Treasury departments, proposed significant updates to healthcare price transparency rules. Comments for the proposed updates were due by March 2, 2026, ...
Texas Children's Hospital pharmacies save $14 million annually with RFID
Texas Children's Hospital, one of the nation's largest pediatric health systems, had a problem: lack of inventory visibility.THE CHALLENGEIt needed to know, with confidence, what medications it had on...
Orthopedics’ quiet profit drains in ASCs
Orthopedics is driving some of the fastest growth in ASCs, but for many operators, higher volume is not translating into stronger margins. Behind the shift of joint and spine cases into outpatient set...
292: Inside the new employer menu of cost-control strategies
292: Inside the new employer menu of cost-control strategies Advisory Board
STAT+: Pharmalittle: We’re reading about pharma delaying launches in Europe, Lilly and Biogen deals, and more
Drugmakers are delaying launches of some new medicines in Europe as the industry grapples with U.S. pressure and pricing policy shifts from President Trump